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Background-—Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug
Administrration–approved treatment for type 2 diabetes mellitus (T2DM). A 3070-subject randomized trial demonstrated a signiﬁcant, 40%
reduction in relative risk among bromocriptine-QR-treated subjects in a prespeciﬁed composite cardiovascular (CV) end point that included
ischemic-related (myocardial infarction and stroke) and nonischemic-related (hospitalization for unstable angina, congestive heart failure [CHF], or
revascularization surgery) end points, but did not include cardiovascular death as a component of this composite. The present investigation was
undertaken to more critically evaluate the impact of bromocriptine-QR on cardiovascular outcomes in this study subject population by (1)
including CV death in the above-described original composite analysis and then stratifying this new analysis on the basis of multiple demographic
subgroups and (2) analyzing the inﬂuence of this intervention on only the “hard” CV end points of myocardial infarction, stroke, and CV death
(major adverse cardiovascular events [MACEs]).
Methods and Results-—Three thousand seventy T2DM subjects on stable doses of ≤2 antidiabetes medications (including insulin) with HbA1c
≤10.0 (average baseline HbA1c=7.0) were randomized 2:1 to bromocriptine-QR (1.6 to 4.8 mg/day) or placebo for a 52-week treatment period.
Subjects with heart failure (New York Heart Classes I and II) and precedent myocardial infarction or revascularization surgery were allowed to
participate in the trial. Study outcomes included time to ﬁrst event for each of the 2 CV composite end points described above. The relative risk
comparing bromocriptine-QR with the control for the cardiovascular outcomes was estimated as a hazard ratio with 95% conﬁdence interval on
the basis of Cox proportional hazards regression. The statistical signiﬁcance of any between-group difference in the cumulative percentage of CV
events over time (derived from a Kaplan–Meier curve) was determined by a log-rank test on the intention-to-treat population. Study subjects were
in reasonable metabolic control, with an average baseline HbA1c of 7.0±1.1, blood pressure of 128/76±14/9, and total and LDL cholesterol of
179±42 and 98±32, respectively, with 88%, 77%, and 69% of subjects being treated with antidiabetic, antihypertensive, and antihyperlipidemic
agents, respectively. Ninety-one percent of the expected person-year outcome ascertainment was obtained in this study. Respecting the
CV-inclusive composite cardiovascular end point, there were 39 events (1.9%) among 2054 bromocriptine-QR-treated subjects versus 33 events
(3.2%) among 1016 placebo subjects, yielding a signiﬁcant, 39% reduction in relative risk in this end point with bromocriptine-QR exposure
(P=0.0346; log-rank test) that was not inﬂuenced by age, sex, race, body mass index, duration of diabetes, or preexisting cardiovascular disease.
In addition, regarding the MACE end point, there were 14 events (0.7%) among 2054 bromocriptine-QR-treated subjects and 15 events (1.5%)
among 1016 placebo-treated subjects, yielding a signiﬁcant, 52% reduction in relative risk in this end point with bromocriptine-QR exposure
(P<0.05; log-rank test).
Conclusions-—These ﬁndings reafﬁrm and extend the original observation of relative risk reduction in cardiovascular adverse events among type 2
diabetes subjects treated with bromocriptine-QR and suggest that further investigation into this impact of bromocriptine-QR is warranted.
Clinical Trial Registration-—URL: http://clinicaltrials.gov. Unique Identiﬁer: NCT00377676 (J Am Heart Assoc. 2012;1:e002279 doi: 10.1161/
JAHA.112.002279)
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ORIGINAL RESEARCHAdministration for the treatment of hyperglycemia in type 2
diabetes mellitus (T2DM) patients in May 2009 under the
trade name Cycloset.
1–3 The primary end points of the 1-year
randomized, controlled Cycloset Safety Trial were the overall
and cardiovascular (CV) safety of bromocriptine-QR versus
placebo in a large population of subjects with T2DM.
4 The
composite cardiovascular event end point included the
ischemic-related end points of myocardial infarction (MI)
and stroke as well as the nonischemic end points of
hospitalization for unstable angina, revascularization surgery,
or congestive heart failure (composite cardiovascular end
point). Analyses to assess various baseline covariates and the
composite cardiovascular end point were prespeciﬁed in the
study’s statistical analysis plan.
4 A prespeciﬁed primary
objective of the study was to assess the cardiovascular
beneﬁt of bromocriptine-QR exposure subsequent to the
demonstration of noninferiority to placebo.
4 A sponsor-
independent, blinded Event Adjudication Committee (EAC)
adjudicated all serious adverse events and the inclusion of
cardiovascular serious adverse events into the composite
cardiovascular end point. The trial results demonstrated a
statistically signiﬁcant, 40% reduction in relative risk for
serious cardiovascular events in subjects exposed to bromo-
criptine-QR versus placebo.
5
The Cycloset Safety Trial, however, did not include CV
death in this prespeciﬁed composite cardiovascular end point,
thus limiting the interpretation of results from that prespec-
iﬁed analysis, in part because the impact of bromocriptine-QR
on the “hard” ischemic CV composite end point of MI, stroke,
and CV death remains unknown. To provide additional insight
into the cardiovascular impact of bromocriptine-QR in T2DM
subjects, we conducted 2 additional post hoc cardiovascular
end-point analyses that each included CV death. The ﬁrst
included CV death as an additional component to the
prespeciﬁed composite cardiovascular end point described
above (CV death-inclusive composite cardiovascular end
point) and assessed the inﬂuence of bromocriptine-QR on
the CV death-inclusive composite cardiovascular end point
stratiﬁed further by various baseline demographic subgroups.
The second analysis evaluated only the “hard” ischemic end
points of MI, stroke, and CV death (major adverse cardiovas-
cular event [MACE] analysis), a standard and critically
important end point for CV outcomes trials.
Methods
Study Design
The protocol for the Cycloset Safety Trial has been previously
published.
4,5 Brieﬂy, this was a 12-month multicenter,
placebo-controlled, double-blind, parallel-group safety and
efﬁcacy study in outpatient subjects with type 2 diabetes
mellitus. Following a 2-week lead-in period, subjects were
randomized in a 2:1 ratio to the usual diabetes treatment (see
below) plus Cycloset or the usual diabetes treatment plus
placebo. Subjects were recruited from general practice and
diabetes clinics across 74 clinical centers in the United States
and Puerto Rico, including 19 Veteran Affairs Medical Centers.
Eligible patients had type 2 diabetes as deﬁned by the
2004 American Diabetes Association (ADA) guidelines,
6 were
between 30 and 80 years old, had a body mass index
<43 kg/m
2, and an HbA1c ≤10.0%. Subjects with New York
Heart Classiﬁcations I and II heart failure were allowed to
participate in the study, as were subjects with a history of
myocardial infarction or coronary revascularization occurring
>6 months before enrollment.
Subjects were required to be on a stable antihyperglycemic
regimen for ≥30 days prior to randomization, consisting of
either lifestyle interventions of medical nutrition therapy and
appropriately prescribed physical activity, oral antihyperglyce-
mic agents (≤2) or insulin (alone or with ≤1 oral antihypergly-
cemic agent), the usual diabetes treatment. During the ﬁrst
6 weeks of the trial, the study drug was titrated weekly by
adding 1 tablet per week (0.8 mg bromocriptine-QR per tablet)
until a maximum tolerated daily dose between 2 and 6 tablets
(1.6 to 4.8 mg/day of bromocriptine-QR) was achieved. The
study drug was taken once daily with the morning meal, within
2 hours of waking. Patients were required to continue their
usual other antihyperglycemic treatments during the ﬁrst 3
months of the study. However, the dosages of the oral agents
or insulin could be modiﬁed as deemed appropriate by the
study site investigator to achieve the target glycemic goals in
the 2004 ADA treatment recommendations.
7 After 3 months,
alterations in the diabetes treatment regimen were allowed if
deemed necessary by the study site investigator; however,
these changes could not include additions that resulted in a
ﬁnal regimen that exceeded 2 oral agents or insulin plus 1 oral
agent, exclusive of the study drug.
During the titration phase, subjects received a weekly
phone call and had ofﬁce visits during weeks 3 and 6. After
titration, subjects were seen during week 12 and then every 3
months until the study’s end (week 52) or early termination.
Subjects were contacted 30 days after completion of the
study drug to record any subsequent adverse events. Physical
examinations and laboratory assessments of hematology and
blood chemistry, including HbA1c, lipids, and liver function
tests, as well as urine analyses were obtained at baseline,
week 24, and week 52. The study protocol was approved by
site-speciﬁc or central institutional review boards.
Outcomes Measures and Statistical Analyses
The CV death-inclusive composite cardiovascular end point of
thepresentinvestigationwasdeﬁnedasthestudy-prespeciﬁed
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composite of myocardial infarction, stroke, coronary revas-
cularization, or hospitalization for angina or CHF) plus the
event of CV death (prespeciﬁed by the EAC of the Cycloset
Safety Trial as death due to sudden cardiac death, MI,
unstable angina, or other coronary artery disease [CAD];
vascular death [eg, stroke, arterial embolism, pulmonary
embolism, ruptured aortic aneurysm, or dissection]; CHF; or
cardiac arrhythmia). All deaths were assessed by the EAC,
consisting of 2 cardiologists and an endocrinologist who
reviewed medical records to determine whether death was
cardiac related. The committee also determined whether
serious adverse events (SAEs) should be included in the
category of the prespeciﬁed cardiovascular end point.
All statistical analyses were conducted on the intention-to-
treat (ITT) population. Total observed person-year outcome
ascertainment for the study end points was derived from the
following subject dispositions: (1) subjects who completed
the 52-week (plus 30-day follow-up) trial on the study drug, (2)
subjects who withdrew from study treatment before week 52
but remained in the study (ie, on study, off drug, and
completing all study visits per protocol) through week 52 plus
the 30-day follow-up period, (3) subjects who withdrew from
the study before week 52 but provided end-point data on a
prespeciﬁed case report form at their projected week 52
termination visit point, and (4) subjects who early-terminated
the study due to a censoring (CV end point) event or other
reason. Statistical methods for the analyses of the CV
death-inclusive composite cardiovascular end point are
essentially the same as previously reported for the prespec-
iﬁed composite cardiovascular end point.
4,5 Analysis of the
composite cardiovascular end point was conducted, adjusting
for baseline covariates including history of stroke and
cardiovascular revascularization surgery and study site. Time
to ﬁrst CV death-inclusive composite cardiovascular event
was further analyzed within the following subgroups: sex
(male versus female), age (≤65 versus >65 years), race (white
versus nonwhite), preexisting macrovascular disease (includ-
ing medical history of myocardial infarction, stroke, CAD,
angina, coronary revascularization, peripheral vascular
disease/revascularization), mean body mass index (BMI;
≤32 versus >32 kg/m
2), and duration of diabetes (≤8 versus
>8 years), and interaction P values for these subgroups were
obtained as well. A Cox regression model was used to
determine the effect of the various demographic subgroups
and their treatment interaction. The main effect of each
subgroup parameter was estimated from the model along with
the treatment parameter estimate, and the treatment by
subgroup interaction parameter was estimated with the
associated P value presented.
Likewise, for the MACE analysis (occurrence of stroke,
myocardial infarction, or CV death) the relative risk comparing
bromocriptine-QR with the control group was estimated as a
hazard ratio (HR) with a 95% conﬁdence interval (CI) on the
basis of Cox proportional hazards regression. Two-sided P
values were calculated with the use of log-rank tests,
unadjusted for multiple testing to assess statistical signiﬁ-
cance of between-group differences in the cumulative
percentage in cardiovascular events generated from the
Kaplan–Meier curves for the CV-death-inclusive composite
cardiovascular end point and the MACE end point. All
analyses were conducted using SAS statistical software
version 9.2 (Cary, NC). The authors had full access to and
take full responsibility for the integrity of the data.
Results
A total of 4074 subjects were screened, and 1004 subjects
were excluded for not meeting eligibility criteria, withdrawal
of consent, or other reasons, yielding 3070 subjects
randomized to study treatment.
5 In total, 91% of the planned
person-year outcome ascertainment was observed in this trial
(2905 of 3207 possible total person-years), with 75% of
bromocriptine-QR subjects and 82% of placebo subjects
providing a week 52 plus 30-day follow-up outcome assess-
ment (see Figure 1 for subject disposition and delineation of
person-year outcome ascertainment). Reasons given for not
completing the study included experiencing an adverse event
(605 total [24% bromocriptine-QR, 11% placebo]); withdrawal
of consent, identiﬁed distinctly as such on the case record
termination visit form (259 total [9% bromocriptine-QR, 7%
placebo]); and other (419 total [13% bromocriptine-QR, 14%
placebo]). A total of 5.5% of patients were lost to follow-up.
Six patients died while on the study drug or within 30 days of
stopping—4 (0.19%) on bromocriptine-QR and 2 (0.20%) on
placebo.
The study population demographics are given in Table 1
and are characteristic of real-world United States T2DM
patients. Their mean age was 60 years, 43% were female, and
17% were African American. Hypertension and hypercholes-
terolemia were prevalent, at 75% and 77%, respectively, and
one third of subjects had preexisting macrovascular disease.
The majority of subjects (74%) were taking oral antihypergly-
cemic agents, whereas 14% were receiving insulin with or
without an oral agent and 12% were managed only with
lifestyle intervention. Metformin was the most commonly
prescribed oral antihyperglycemic agent (58%), followed by
sulfonylureas (37%). The majority of patients were taking
cardioprotective medications (antihypertensives, statins,
ﬁbrates, and anticoagulants), with 91% taking ≥1 such agent
(Table 2). The average baseline values for HbA1c, fasting
glucose, fasting plasma lipid, and blood pressure suggest
moderate to good control of these important disease metrics
(Table 1). Creatinine level, body mass index, and waist
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duration of diabetes of 8 years (Table 1). Overall, there were
no differences in baseline characteristics between the groups
that would not be expected by chance (Tables 1 and 2).
In this 1-year trial, 72 of 3070 subjects experienced ≥1o f
the CV death-inclusive composite cardiovascular end points.
Fewer patients experienced this composite end point on
bromocriptine-QR (1.9%) versus placebo (3.2%), yielding a
statistically signiﬁcant 39% relative risk reduction (HR 0.61,
95% CI 0.38 to 0.97; P=0.02). The between-group difference
in cumulative percent of cardiovascular end-point events over
the duration of the study was signiﬁcant in favor of
bromocriptine-QR (log-rank test, P=0.0346) (Figure 2).
Table 3 depicts number of events and hazard ratios for the
time to ﬁrst CV death-inclusive composite cardiovascular end
point as well as for each of the components in this composite.
Each component of this composite end point had a point
estimate <1.0, although none of the hazard ratios for the
individual components reached statistical signiﬁcance.
In this CV death-inclusive composite cardiovascular end-
point analysis (which included revascularization surgery), the
time to ﬁrst composite end point was assessed as the primary
end point, and thus coronary revascularization following a
primary event such as MI or hospitalization for angina would
not be assessed in this Cox analysis. We therefore investi-
gated the inﬂuence of bromocriptine-QR treatment on the
revascularization surgery incidence rate following a primary
CV composite end-point event. Similar to what was seen with
coronary revascularization as a primary end point, fewer
patients receiving bromocriptine-QR underwent coronary
revascularization following a primary CV end point (0.44%)
compared with placebo (1.08%), yielding a 57% relative risk
reduction in coronary revascularization subsequent to a
primary CV event that approached statistical signiﬁcance
(95% CI 0.18 to 1.03) (Table 3).
Men, older patients (>65 years), patients with longer
duration of diabetes (>8 years), whites, and patients with
preexisting macrovascular disease exhibited a numerically
Figure 1. Subject disposition. ITT indicates intention-to-treat.
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Hgreater number of CV events in the study. However, the CV
death-inclusive composite cardiovascular end-point relative
risk reduction observed for patients receiving bromocriptine-
QR versus placebo was consistent and not inﬂuenced by age,
race, sex, body mass index, duration of diabetes, or preex-
isting macrovascular disease (Table 4). That is, treatment by
variable interaction was tested, and no signiﬁcant (P<0.05)
interactions were observed.
An analysis of bromocriptine-QR impact on the MACE (MI,
stroke, CV death) end point revealed a 52% relative
risk reduction in adverse cardiovascular event rate by
Table 1. Baseline Demographics and Laboratory Vital
Measures of Study Population
Variable
Bromocriptine-QR
(N=2054)
Placebo
(N=1016)
Mean age 59.5 (±10.2) 60.2 (±9.97)
Duration of diabetes diagnosis,
mean (±SD)
7.9 (±7.42) 8.0 (±7.41)
Male sex, n (%) 1141 (56) 598 (59)
White race, n (%) 1381 (67) 698 (69)
Black race, n (%) 348 (17) 168 (16.5)
Hispanic, n (%) 277 (13.5) 131 (13)
Asian, n (%) 22 (1.1) 10 (1.0)
Other, n (%) 26 (1.3) 9 (0.9)
Hypertension, n (%) 1548 (75) 767 (75.5)
Angina pectoris, n (%) 214 (10) 101 (10)
Myocardial infarction, n (%) 186 (9.1) 106 (10.4)
Revascularization surgery, n (%) 204 (10) 128 (13)
Stroke, n (%) 86 (4.2) 63 (6.2)
Hypercholesterolemia, n (%)* 1575 (77) 767 (75.5)
Hypertriglyceridemia, n (%)* 853 (41.5) 422 (41.5)
Current smoker, n (%) 306 (15) 133 (13)
Former smoker, n (%) 802 (39) 419 (41)
Laboratory and vital measures
HbA1c (%), mean (±SD) 7.0 (±1.0) 7.0 (±1.1)
Fasting glucose (mg/dL),
mean (±SD)
142 (±41) 141 (±41)
Total cholesterol (mg/dL),
mean (±SD)
179 (±43) 177 (±39)
LDL cholesterol (mg/dL),
mean (±SD)
98 (±33) 97 (±30)
HDL cholesterol (mg/dL),
mean (±SD)
46 (±12) 46 (±12)
Triglycerides (mg/dL),
mean (±SD)
181 (±145) 175 (±122)
Systolic blood pressure (mm Hg),
mean (±SD)
128 (±14) 129 (±14)
Diastolic blood pressure (mm Hg),
mean (±SD)
76 (±9) 76 (±9)
Creatinine (mg/dL), mean (±SD) 1.1 (±0.2) 1.1 (±0.2)
Body mass index (kg/m
2),
mean (±SD)
32.4 (±5.1) 32.3 (±5.1)
Waist circumference (inches),
mean (±SD)
41.8 (±5.1) 42.0 (±5.5)
SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
*Based on history as assessed by study site investigator.
Table 2. Baseline Antihyperglycemic and Cardioprotective
Medications of Study Population
Variable
Bromocriptine-QR
(N=2054)
Placebo
(N=1016)
Diabetes treatment, n (%)
Diet only 257 (12.5) 114 (11)
One oral hypoglycemic agent 806 (39) 403 (40)
Two oral hypoglycemic agents 686 (33) 323 (32)
Oral agent plus insulin 171 (8) 98 (10)
Insulin only 133 (6) 78 (8)
Not reported 1 0
Antidiabetes medications by
agent, n (%)
Metformin 1209 (59) 581 (57)
Rosiglitazone 233 (11) 111 (11)
Pioglitazone 161 (8) 83 (8)
Sulfonylurea/glinide 759 (37) 392 (39)
Other 29 (1) 19 (2)
Cardioprotective medications by
class, n (%)
ACE inhibitors 994 (48) 477 (47)
Angiotensin II receptor inhibitors 271 (13) 135 (13)
b-Blockers 452 (22) 247 (24)
Diuretics, thiazide 445 (22) 233 (23)
Sulfamides, loop diuretics 166 (8) 89 (9)
Other diuretic* 75 (4) 49 (5)
Calcium channel blockers
† 362 (18) 202 (20)
Hmg CoA reductase inhibitor 1165 (57) 594 (58)
Fibrate 157 (8) 78 (8)
Platelet aggregation inhibitors 943 (46) 500 (49)
Cardioprotective medications by
number, n (%)
Taking 1 cardioprotective agent 376 (18) 184 (18)
Taking 2 cardioprotective agents 411 (20) 224 (22)
Taking 3 cardioprotective agents 390 (19) 183 (18)
Taking ≥4 cardioprotective agents 678(33) 345 (34)
*Other diuretics include aldosterone inhibitors, low-ceiling diuretics.
†Calcium channel blockers include dihydropyridine, phenylalkylamine, benzothiazepine.
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(Table 3). The MACE Kaplan–Meier curve (Figure 3) demon-
strates a clear separation in MACE cumulative events in favor
of those subjects randomized to bromocriptine-QR therapy
(log-rank test, P<0.05). A sensitivity analysis was conducted
on the time to ﬁrst MACE end point for only the on-treatment
population (ie, outcome ascertainment time contributed only
while actively on treatment) and similarly revealed a hazard
ratio of 0.452 with a 95% CI of 0.205 to 0.996 (P<0.05) in
favor of bromocriptine-QR.
Discussion
The current ﬁndings of 39% and 52% relative risk reductions in
the CV death-inclusive composite cardiovascular and MACE
end points, respectively, among bromocriptine-QR versus
placebo subjects in the Cycloset Safety Trial corroborate and
extend the original observations from this trial on bromocrip-
tine-QR impact on prespeciﬁed adverse cardiovascular out-
comes that excluded CV death.
5 Moreover, the effect of
bromocriptine-QR on the CV death-inclusive composite
Figure 2. Time to composite end point of cardiovascular serious adverse events including nonfatal myocardial infarction (excluding silent MI),
stroke, hospitalization for angina or hospitalization for heart failure, coronary revascularization, and cardiovascular death. SAEs indicates serious
adverse events; MI, myocardial infarction.
Table 3. Impact of Bromocriptine-QR on CV Death-Inclusive Composite Cardiovascular End Point and Individual Components of
the Composite as Well as on the MACE End Point
Bromocriptine-QR
(N=2054), n (%)*
Placebo
(N=1016), n (%)*
Hazard Ratio
(95% CI)
CV death-inclusive composite cardiovascular end point 39 (1.9) 33 (3.2) 0.61 (0.38 to 0.97)
Myocardial infarction 7 (0.3) 9 (0.9) 0.41 (0.15 to 1.11)
Stroke 5 (0.2) 6 (0.6) 0.44 (0.13 to 1.43)
Hospitalization for angina 9 (0.4) 9 (0.9) 0.52 (0.21 to 1.30)
Hospitalization for heart failure 9 (0.4) 6 (0.6) 0.77 (0.27 to 2.16)
Coronary revascularization 11 (0.5) 8 (0.8) 0.72 (0.29 to 1.80)
CV death 4 (0.2) 2 (0.2) 0.48 (0.07 to 3.43)
Coronary revascularization following a primary end point (ie, CABG after MI) 9 (0.4) 11 (1.1) 0.43 (0.18 to 1.03)
MACE composite—myocardial infarction, stroke, CV death 14 (0.7) 15 (1.5) 0.48 (0.23 to 1.00)
CI, conﬁdence interval; CV, cardiovascular; CABG, coronary artery bypass graft; MACE, major cardiovascular adverse event; MI, myocardial infarction.
*Percentage of events per total number per group: 2054 bromocriptine-QR, 1016 placebo.
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subgroup indicates that the magnitude and direction of the CV
disease risk reduction of bromocriptine-QR was similar
regardless of age, sex, BMI, race, preexisting CV disease, or
duration of diabetes (Table 4). Realizing the limitation of the
small number of events in this study, this subgroup interaction
analysis was conducted to explore the possibility that a
spurious subject demographic among those examined that
could inﬂuence cardiovascular event rate may have inﬂuenced
the outcome observed. The results of this analysis suggested
no such occurrence. These ﬁndings are best appreciated
when viewed in the context of the unique study population
and trial design employed in the Cycloset Safety Trial, which
had few restrictions on enrollment of subjects with comorbid
conditions commonly associated with type 2 diabetes (such
as CHF or preexisting cardiovascular disease or events).
Moreover, approximately one third of the study subjects had
preexisting CV disease at baseline; most were taking cardio-
protective medications and 2 antihyperglycemic medications
(including insulin) prior to randomization.
5 Consequently, the
study population on average was in moderate to good
metabolic control, with a median HbA1c of 7.0±1.0%,
plasma triglyceride level of 179±137 mg/dL, plasma LDL
level of 98±32 mg/dL, and systolic blood pressure of
128±14 mm Hg.
5 In addition, investigators were instructed
to adjust concomitant diabetes treatments (including glyce-
mic-lowering agents) in order to attempt to achieve recom-
mended ADA therapeutic targets. This trial design provided
the opportunity to assess the effect of bromocriptine-QR on
cardiovascular outcomes in a T2DM population that, on
average, was in relatively good metabolic control and against
a background of routine diabetes standard of care.
Despite the generally good metabolic control of the
population and the instruction for investigators to intervene
during the trial to attempt to achieve the glycemic goals of the
American Diabetes Association, the placebo arm of the trial
had a serious cardiovascular event rate for the CV death
inclusive end point of 3.2% and of the MACE end point of 1.5%.
These event rates were not different from those of other large
T2DM cardiovascular outcomes trials. For instance, in the
ADVANCE (Action in Diabetes and Vascular Disease) and
ACCORD (Action to Control Cardiovascular Risk in Diabetes)
Table 4. Impact of Bromocriptine-QR on CV Death-Inclusive Composite Cardiovascular End Point Stratiﬁed by Various
Demographic Subgroups
Bromocriptine-QR Placebo
Hazard Ratio (95% CI)
Treatment by Subgroup
Interaction, P Value N
CV Events, No.
People (%) N
CV Events, No.
People (%)
CV-death-inclusive composite
cardiovascular end point
2054 39 (1.9) 1016 33 (3.2) 0.61 (0.38 to 0.97)
Sex
Male 1141 31 (2.7) 598 26 (4.3) 0.65 (0.39 to 1.09) 0.77
Female 913 8 (0.9) 418 7 (1.7) 0.54 (0.19 to 1.49)
Age, years
>65 601 21 (3.5) 315 18 (5.7) 0.66 (0.35 to 1.25) 0.88
≤65 1453 18 (1.2) 701 15 (2.1) 0.59 (0.30 to 1.17)
Duration of DM disease, years
>8 1015 24 (2.4) 518 21 (4.1) 0.62 (0.34 to 1.11) 0.96
≤8 1038 15 (1.4) 496 12 (2.4) 0.61 (0.28 to 1.30)
Race
White 1381 33 (2.4) 698 26 (3.7) 0.67 (0.40 to 1.13) 0.46
Nonwhite 673 6 (0.9) 318 7 (2.2) 0.42 (0.14 to 1.24)
Preexisting macrovascular disease
Yes 501 31 (6.2) 271 22 (8.1) 0.80 (0.46 to 1.38) 0.15
No 1553 8 (0.5) 745 11 (1.5) 0.34 (0.14 to 0.86)
Body mass index, kg/m
2
≤32 1023 20 (2.0) 522 17 (3.3) 0.63 (0.33 to 1.21) 0.87
>32 1031 19 (1.8) 494 16 (3.2) 0.59 (0.30 to 1.15)
CV indicates cardiovascular; DM, diabetes mellitus.
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Htrial standard treatment arms, the MACE rate per 1000
person-years was 21.2 and 19.6, respectively, which is similar
to that observed in the placebo arm of the Cycloset Safety Trial
(16.4). The Cycloset Safety Trial population was similar to
ADVANCE and ACCORD in age, duration of diabetes, and sex,
but the average baseline lipids, blood pressure, and HbA1c
metabolic parameters were indicative of better control in the
Cycloset Safety Trial study population.
8,9 Intensive glucose-
lowering therapies over a 3.5- to 5-year period in the ACCORD
and ADVANCE studies did not result in any signiﬁcant
reduction in nonfatal MI, nonfatal stroke, and cardiovascular
death (MACE). In contrast, bromocriptine-QR therapy for only
1 year was associated with a 52% relative risk reduction in the
MACE end point. These results occurred in the midst of
modest improvements in hyperglycemia, hypertension, plasma
triglyceride level, and heart rate (modest effects due primarily
to the generally good control of these parameters represented
in the baseline bromocriptine-QR and placebo populations),
5
which may have contributed to the CV outcome observed.
The results of analyses of the original prespeciﬁed CV
composite(includingischemicandnonischemiccardiovascular
end points
5), the present CV-death-inclusive composite, and
the MACEs (only ischemic cardiovascular end points) are
internally consistent and suggest a positive impact of bromo-
criptine-QR on adverse CV outcomes in this T2DM population.
The results of these analyses and the subgroup interaction
analysis conducted in this sudy in total suggest that the
observed effect of bromocriptine-QR on CV outcomes is not
driven by a particular component of the CV composite studied
or by any particular subject demographic investigated. The
obvious question that remains is how bromocriptine-QR
exposure produced this consistently observed result on
cardiovascular outcomes. The Cycloset Safety Trial did not
includeassessmentofanymechanisticdata,soanyinsightson
possiblemechanismsforthisbromocriptine-QRresponseatthe
present time must be gleaned from other existing information
relating to the impact of bromocriptine on cardiometabolic
physiology. The scientiﬁc literature on this topic from both
preclinical and clinical studies is brieﬂy summarized as follows.
Timeddailybromocriptineadministrationtoinsulin-resistant
animals normalizes multiple hypothalamic neurophysiological
derangements characterized by low hypothalamic dopaminer-
gic tone, elevated ventromedial hypothalamic noradrenergic
and serotonergic activity, and elevated paraventricular hypo-
thalamic neuropeptide Y and corticotrophin-releasing factor
levels.
10 This cluster of derangements can potentiate overac-
tivation of the hypothalamic-pituitary-adrenal axis (ie, cortisol
release) and of the sympathetic nervous system drive to the
liver, adipose, and the cardiovascular system,
10 as well as
increased responsiveness to sympathetic stimulation.
11
Increased sympathetic activity in adipose results in increased
free fatty acid (FFA) mobilization,
12,13 which in turn can act to
induce hepatic very low-density lipoprotein triglyceride synthe-
sis and secretion (postprandially), lipotoxicity, secretion of
inﬂammatory proteins, and insulin resistance.
14 Increased
cortisol and sympathetic drive in the liver increases hepatic
glucose output and decreases hepatic glucose disposal,
particularly after a meal, which potentiates postprandial
Figure 3. Time to composite end point of nonfatal myocardial infarction (excluding silent MI) or stroke or cardiovascular death (MACE) in ITT
population for bromocriptine-QR and placebo groups. SAEs indicates serious adverse events; MI, myocardial infarction; and ITT, intention-to-treat.
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Hhyperglycemia.
15–17 Increased sympathetic drive to the vascu-
lature induces hypertension
18,19 and to the heart (including as
part of cardiac autonomic neuropathy) can be a major
contributor to cardiac disease.
20–26 Increases in (postprandial)
plasma FFA, glucose, and triglycerides as well as in inﬂamma-
tory proteins and noradrenaline under the vasoconstrictive
inﬂuence of elevated sympathetic nervous system tone can
potentiate generation of vascular reactive oxygen species and
increase inﬂammation, endothelial dysfunction, hypercoagula-
tion,andarteriosclerosis.
27–34Andincreasedsympathetictone
itself is a contributor to insulin resistance syndrome.
35–39
Timed daily administration of bromocriptine to insulin-
resistant animals acts centrally to reverse these sequelae of
neuroendocrine and metabolic events (overactive hypotha-
lamic pituitary adrenal axis and sympathetic tone and insulin
resistance syndrome, respectively) (reviewed in
10). Finally,
and potentially of signiﬁcant import, bromocriptine therapy of
hypertensive, insulin-resistant, arteriosclerotic rats has been
shown to reduce arterial stiffness and endothelial nitric oxide
synthase uncoupling,
40 a phenomenon seen with diabetes
that results in reduced nitric oxide generation and overpro-
duction of reactive oxygen and nitrogen species in vessel
walls that can induce prodigious damage to the vasculature.
41
It is not known whether the use of bromocriptine to correct
these hypothalamic aberrations that precipitate multiple
parallel pathophysiological events known to potentiate CV
disease is involved in its ability to reduce the MACE end point
in the present study. Although not measured in the Cycloset
Safety Trial, bromocriptine-QR therapy simultaneously
reduced postprandial glucose, FFA, and triglyceride levels in
T2DM subjects in other studies.
1,2 In the Cycloset Safety Trial,
bromocriptine-QR produced meaningful reductions in HbA1c
and blood pressure among those with elevated HbA1c (≥7.5%)
or blood pressure (systolic blood pressure >130 mm Hg) at
baseline.
42,43 And the general sympatholytic effect of bromo-
criptine in humans has been well appreciated for many
years.
44–46 Although these ﬁndings offer intriguing possibil-
ities for identifying pathways by which bromocriptine-QR may
produce the results on the cardiovascular end points reported
here, much additional research in this area is needed to fully
delineate these mechanisms.
The major limitation of this investigation is the inability to
fully assess the potential impact of bromocriptine-QR across
various demographic subgroups. Because of the number of
outcomes, subgroup demographic groupings needed to be
broad to assess the impact of bromocriptine-QR on any one of
them. Multivariate models of analysis were also not possible
on the subgroups investigated. Also, because of the 1-year
duration of the study, there were too few deaths to comment
on the intervention’si n ﬂuence on total mortality. Nonethe-
less, the relative risk reduction of the CV death-inclusive
composite cardiovascular end point (and the supportive
analysis across various subgroups) and of the MACE end
point in the bromocriptine-QR-exposed group reafﬁrms and
extends the previous observation of bromocriptine-QR treat-
ment on CV outcomes in T2DM subjects.
5
Conclusions
Treatment with bromocriptine-QR reduced the CV death-
inclusive composite cardiovascular end point by 39% in T2DM
subjects after 1 year of treatment, and this observed relative
risk reduction was consistent regardless of age, duration of
disease, race, sex, or preexisting CV disease. Furthermore,
among such subjects with type 2 diabetes receiving com-
monly prescribed diabetes therapies, bromocriptine-QR sig-
niﬁcantly reduced the relative risk for the composite end point
of myocardial infarction, stroke, and cardiovascular death
(MACE) by 52%.
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